Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

    Not Recruiting
  • End date
    Apr 11, 2022
  • participants needed
  • sponsor
    Novartis Pharmaceuticals
Updated on 16 June 2021
Novartis Pharmaceuticals
Primary Contact
Novartis Investigative Site (0.0 mi away) Contact
+21 other location
measurable disease
platinum doublet
egfr t790m


To determine the efficacy and safety of Nivolumab in combination with EGF816 and of Nivolumab in combination with INC280 in previously treated NSCLC patients


This study has two arms:

Arm 1 (EGF816 + nivolumab) is currently closed to new enrollment.

Arm 2 (INC280 + nivolumab) is open and enrolling as planned.

Condition Non-Small Cell Lung Cancer
Treatment INC280, Nivolumab, EGF816
Clinical Study IdentifierNCT02323126
SponsorNovartis Pharmaceuticals
Last Modified on16 June 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note